The race for a coronavirus vaccine heats up

Biotech shares, led by AstraZeneca, are lifted in the race to come up with a coronavirus vaccine.

Shares in AstraZeneca bounced this week after the US government signalled that it is considering fast-track approval for the group’s Covid-19 vaccine. In April AstraZeneca agreed a deal with Oxford University, which originally discovered the vaccine, to develop and distribute it. 

The government could ask the US Food and Drug Administration (FDA) to grant an “emergency use authorisation” (EUA) based on data from the final-stage UK trial, rather than wait for the more extended study normally required by US regulators. Such a move, possible as early as September, would allow President Donald Trump to claim he has “turned the tide” on the virus. Not so fast, say Rhys Blakely and Henry Zeffman in The Times. AstraZeneca says it is “too early” to begin talks with US regulators about an EUA. Nonetheless, 17,000 people have been enrolled in trials in Britain, South Africa and Brazil. So if enough data emerged to convince AstraZeneca to apply for an EUA, the FDA would be under pressure to grant it quickly. It has already approved 21 Covid-19 drugs, including an antibody treatment, on an emergency basis.

Meanwhile, says Bloomberg, Pfizer and BioNTech claim that their joint Covid-19 vaccine is “on track” to be submitted for regulatory review “as early as October”. The companies, which recently clinched a $2bn deal to supply 100 million doses to the US government, released more detailed data from early-stage trials suggesting that the drug was “well tolerated” with “mild to moderate fever in fewer than 20% of participants”.

Recommended

Big tech smashes expectations with bumper profits
Tech stocks

Big tech smashes expectations with bumper profits

Big tech companies have reported profits far in excess of expectations, with Apple, Alphabet and Microsoft generating a combined $56.8bn. Saloni Sarda…
28 Jul 2021
Oil is taking a well-earned rest. But the bull market isn’t done yet
Oil

Oil is taking a well-earned rest. But the bull market isn’t done yet

The oil price has more than doubled in the last five years. It’s come off the boil recently, but in the longer term, things are still looking good. Do…
28 Jul 2021
Why you should treat whole-life insurance policies with extreme caution
Personal finance

Why you should treat whole-life insurance policies with extreme caution

Whole-life insurance policies are often marketed to people in their 50s and over. But there are significant drawbacks and you could end up with nothin…
28 Jul 2021
I wish I knew what an index was, but I’m too embarrassed to ask
Too embarrassed to ask

I wish I knew what an index was, but I’m too embarrassed to ask

The FTSE 100 is probably the best-known stockmarket index in the UK. But what exactly is an index?
27 Jul 2021

Most Popular

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
An absurdly cheap healthcare stock to buy now
Share tips

An absurdly cheap healthcare stock to buy now

The pandemic has vastly accelerated the shift towards telehealth, making Cigna a long-term buy
20 Jul 2021